Mitsubishi UFJ Trust & Banking’s Arbutus Biopharma ABUS Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$152K	Buy	+31,688	New	+$139K	﹤0.01%	1399

Other funds holding ABUS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

FCH

Freestone Capital Holdings Seattle, Washington $3.86B AUM 26.3% 1-Year Est. Return

LWA

Ledgewood Wealth Advisors Exeter, New Hampshire $188M AUM 18.45% 1-Year Est. Return

CCA

Carrera Capital Advisors Troy, Michigan $675M AUM 17.92% 1-Year Est. Return

CCIA

Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's ABUS Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 31,688 shares worth $152K. The stake represents ﹤0.01% of the portfolio and ranks #1399 among its holdings.

51 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Mitsubishi UFJ Trust & Banking held 31,688 shares of Arbutus Biopharma worth $152K as of Q2 2026.
Arbutus Biopharma was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
Arbutus Biopharma made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1399 holding.
51 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.